{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-124739","form_type":"8-K","ticker":"RNAZ","cik":"0001829635","company_name":"Transcode Therapeutics, Inc.","filed_at":"2023-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.824901+00:00","generated_at":"2026-06-07T15:42:30.914366+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"TransCode Therapeutics amends bylaws, reduces stockholder quorum from majority to one-third","bullets":["Board approved amendment to Amended and Restated Bylaws on Dec 8, 2023.","Quorum for stockholder meetings reduced to one-third of outstanding shares entitled to vote.","Amendment also revises procedures for adjournment of stockholder meetings.","Effective immediately upon adoption; amends Sections 4(e) and 5 of Article I."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-124739","json":"https://secwatch.observer/filing/0001104659-23-124739.json","markdown":"https://secwatch.observer/filing/0001104659-23-124739.md","text":"https://secwatch.observer/filing/0001104659-23-124739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923124739/0001104659-23-124739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923124739/tm2332527d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:42:30.914366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"94c939255fc3d43d68d98353a6d25b4b2d5f4ad8","claim":"Transcode Therapeutics, Inc.: Amended bylaws to revise stockholder meeting adjournment procedures and reduce quorum requirement from a majority to one-third of outstanding shares entitled to vote (effective 2023-12-08).","evidence_excerpt":"On December 8, 2023, the Board of Directors of TransCode Therapeutics, Inc., a Delaware corporation (the “Company”) authorized, approved and adopted an amendment to the Company’s Amended and Restated Bylaws to (i) revise certain provisions relating to stockholder meeting adjournment procedures and (ii) reduce the quorum requirement for meetings of the Company’s stockholders from a majority of the Company’s outstanding shares entitled to vote, represented in person or by proxy to one-third of the Company’s outstanding shares entitled to vote, represented in person or by proxy (the “Bylaw Amendment”). The Bylaw Amendment became effective immediately upon its adoption and amended Sections 4(e) and 5 under Article I of the Company’s Amended and Restated Bylaws.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923124739/0001104659-23-124739-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-12-08"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}